Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278382 | 0.95 | REN (0.44) | RENCTSSCTSK | |
| SCHEMBL23005016 | 0.83 | REN (0.46) | RENCTSSCTSK | |
| SCHEMBL23004963 | 0.74 | NPY5R (0.42) | RENCTSSCTSK | |
| SCHEMBL30278355 | 0.74 | NPY5R (0.39) | REN | |
| SCHEMBL6830434 | 0.71 | REN (0.56) | REN | |
| SCHEMBL3827253 | 0.71 | REN (0.58) | RENCTSSCTSK | |
| SCHEMBL23022839 | 0.70 | ATM (0.47) | REN | |
| SCHEMBL3819130 | 0.70 | CTSS (0.61) | RENCTSSCTSK | |
| SCHEMBL3823930 | 0.70 | REN (0.56) | RENCTSSCTSK | |
| SCHEMBL8140311 | 0.69 | REN (0.60) | RENCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | REN 2951/4885CTSS 428/4885CTSK 2871/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | REN 2951/4885CTSS 428/4885CTSK 2871/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | REN 2951/4885CTSS 428/4885CTSK 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.